Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH
Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the
[Read More...]
Merck
PharmaShots Weekly Snapshot (Jul 27- 31, 2020)
1. Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease Published: Jul 31, 2020 |
[Read More...]
Merck’s MK-6482 Receives the US FDA’s Breakthrough Therapy Designation to Treat Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Shots: The designation is based on P-II study evaluating MK-6482 in patients with VHL-associated RCC with nonmetastatic RCC tumors >3cms in size, unless
[Read More...]
PharmaShots Weekly Snapshot (Jul 20- 24, 2020)
1. Gilead and Galapagos’ Jyseleca (filgotinib) Receive the CHMP’s Positive Opinion for Moderate to Severe Rheumatoid Arthritis Published: Jul 24, 2020 | Tags: Gilead,
[Read More...]
PharmaShots Weekly Snapshot (Jul 13- 17, 2020)
1. Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags:
[Read More...]
Merck and Bayer Receive the US FDA’s Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Chronic Heart Failure with HFrEF
Shots: The NDA is based on P-III VICTORIA study assessing vericiguat (qd, (titrated up to 10mg) vs PBO when given in combination with
[Read More...]
Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV
Shots: Dewpoint to receive up to $305M as up front and milestone along with royalties on sales of any approved product emerges under
[Read More...]
PharmaShots Weekly Snapshot (Jul 06 – 10, 2020)
1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul
[Read More...]
The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU
Shots: The EC has signed an agreement to supply Roche’s RoActemra and Merck’s Rebif in 27 EU member states willing to buy the
[Read More...]
Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target
Shots: Foghorn will receive an upfront, development, regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any
[Read More...]